Deuterium

Other Names

2HDDiplogenHeavy hydrogenHydrogen-2²H

Synopsis

Deuterium: A Comprehensive Reference Article

1. Identity: Chemical Nature, Natural Sources, and Forms

Chemical Identity

Deuterium (²H or D), the other stable hydrogen isotope, contains one proton and one neutron in its nucleus. It is a stable, non-radioactive isotope of hydrogen and has an atomic weight of 2.0144. There are three isotopic forms of hydrogen in nature: protium (¹H), deuterium (²H), and tritium (³H). Essentially all deuterium in the universe is thought to have been produced at the time of the Big Bang, and has endured since that time. Deuterium is not radioactive, and does not represent a significant toxicity hazard.

The difference in mass causes deuterium to behave slightly differently in chemical reactions compared to protium, a phenomenon known as the kinetic isotope effect. The heavier deuterium atom forms a stronger, lower-energy chemical bond. Breaking a deuterium bond requires a slightly greater amount of energy than breaking a protium bond, causing chemical reactions involving deuterium to proceed at a slower rate.

Since its discovery by Harold Urey in 1932, deuterium has attracted increased amounts of attention from the scientific community, with many previous works aimed to uncover its biological effects on living organisms. Urey received the Nobel Prize in Chemistry in 1934 for this discovery.

Natural Abundance and Distribution

The amount inferred for normal abundance of deuterium was so small — only about 1 atom in 6,400 hydrogen atoms in seawater (156 parts per million) — that it had not noticeably affected previous measurements of (average) hydrogen atomic mass. It has an abundance of 0.015% on Earth and mostly exists in the form of heavy water (D₂O) in seawater and ordinary water. It is present in natural waters in the form of HDO, at a concentration of 16.8 mmol/L, equivalent to approximately 150 ppm.

A concentration of heavy water and semi-heavy water contained in water of nature differs depending on places to be collected, but in level grounds, the concentration is about 150 ppm, most of which are semi-heavy water. One of the natural sources of deuterium-depleted water is glacier water, which has a deuterium concentration of 135 ppm — not significantly lower than the 150 ppm found in ordinary water.

Common Forms and Preparations

Deuterium is encountered in health and supplement contexts in several distinct forms:

Deuterium Oxide (D₂O) / Heavy Water: When deuterium bonds with oxygen, it forms deuterium oxide (D₂O), commonly known as heavy water. Heavy water has slightly elevated phase transition points, with a freezing point of 3.8°C and a boiling point of 101.4°C.
Deuterium-Depleted Water (DDW): Deuterium-depleted water (DDW) is distilled, microbiologically pure water with a D/(D+H) isotopic content lower than the value of 145 ppm of natural water. DDW of controlled isotopic concentration D/(D+H) within the range of 20–120 ppm, of quality similar to distilled water, can currently be produced.
Deuterium-Depleted Diet: Extracellular depletion acts as a metabolic therapeutic adjuvant and it can be introduced by diet and drinks.
Deuterated Pharmaceutical Compounds: A deuterated drug is a small molecule medicinal product in which one or more of the hydrogen atoms in the drug molecule have been replaced by the heavier stable isotope deuterium.

Production Methods

To produce deuterium-depleted water from commonly used water, the following techniques have been known: repeated distillation utilizing a slight difference in physical property between hydrogen and deuterium, and a water electrolysis method. A method has been described that could be the basis for the first industrial-scale production of deuterium-depleted water. It involves a platinum catalyst that quickly and efficiently removes deuterium from water using a combination of cold and hot temperatures. In laboratory-scale tests, this technique reduced the amount of deuterium in water from about 145 parts per million to 125 parts per million. All current methods are expensive, consume much energy, and pollute the environment. The so-called Girdler Sulfide (GS) process is the most efficient, but it uses toxic chemicals.

2. Traditional and Historical Use

Deuterium, as a specific substance, has no traditional or historical use in any indigenous, herbal, or folk medicine tradition. Since its discovery by Harold Urey in 1932, deuterium has attracted increased amounts of attention from the scientific community. Its study and application are entirely products of twentieth- and twenty-first-century science.

The earliest biological applications of deuterium centered on its use as a scientific tracer. In chemistry, biochemistry, and environmental sciences, deuterium is used as a non-radioactive, stable isotopic tracer, for example, in the doubly labeled water test.

The first recognition that deuterium depletion might have biological significance in the context of cancer came from Hungarian research. In the early 1990s, Hungarian molecular biologist Gábor Somlyai, PhD, recognized that a shortage of deuterium can cause significant changes in living organisms. These studies—initiated by pioneering research published in 1993 that first demonstrated the cell growth-inhibiting effect of DDW—proved to be a significant milestone in exploring alternative cancer therapies.

The contemporary use of DDW as a health supplement is concentrated principally in Hungary and parts of Eastern Europe, where it has been developed primarily as a potential adjunct to cancer therapy. Deuterium-depleted water is not approved by the Japanese Ministry of Health, Labor and Welfare, but is approved in Hungary as an anticancer drug for animals, and is taken by many cancer patients and others.

3. Key Constituents, Active Compounds, and Mechanisms of Action

The Kinetic Isotope Effect (KIE)

Researchers have defined a deuterium kinetic isotope effect (KIE) as a measure of the change in the rate of a reaction when deuterium replaces hydrogen, compared to the reaction when hydrogen is present. Deuterium forms stronger carbon-deuterium (C-D) bonds compared to carbon-hydrogen (C-H) bonds. This difference arises from deuterium's higher atomic mass, which reduces vibrational frequency and increases bond stability. The kinetic isotope effect slows enzymatic cleavage of C-D bonds, altering drug metabolism.

Effects on ATP Synthase and the Mitochondrial Electron Transport Chain

ATP synthase (F₀F₁ ATPase), an inner mitochondrial membrane enzyme complex, is a molecular motor that uses protonation to generate a wheel-like rotation to catalyse the synthesis of ATP, the most important energy currency in living systems. During mitochondrial electron transport, protons are pumped from the matrix to the intermembrane space by the electron transport chain (ETC) complexes I, III, and IV by a mechanism coupling electron transport to proton passage. The proton gradient thus formed and the consequent proton motive force rotates the rotor part of F₀. This torque is transmitted by the stalk part of ATP synthase to F₁, which produces one ATP with the passage of approximately three protons.

In mitochondria, the release of a deuteron into the matrix side half-channel of F₀ is likely to be slower than that of a proton. A temporary stutter of the rotor is expected during the passage of a deuteron. Deuteronation may also slow down electron transfer in the electron transport chain (ETC) by interfering with proton-coupled electron transport reactions (PCET), and increase free radical production through the leakage of temporarily accumulated electrons at the downstream complexes.

Proton Tunneling and Enzyme Selectivity

Studies on metabolic pathways clearly show that the enzymes involved in metabolizing organic molecules in the mitochondria result in the delivery of deuterium-depleted protons to the mitochondrial intermembrane space. In part, this feat is achieved through several dehydrogenase enzymes that bind nicotinamide adenine dinucleotide (NAD) and flavin adenine dinucleotide (FAD) and exploit proton tunneling to transfer a hydride ion from a carbon atom in the substrate to NAD⁺ to form NADH. Deuterons have been found to be 20 times less efficient at tunneling than protons, and this results in a high deuterium kinetic isotope effect (KIE). Mitochondrial NADH dehydrogenase, also known as Complex I multimeric enzyme complex, ultimately delivers protons to the intermembrane space, and these protons are highly unlikely to be ²H.

Cellular metabolism incorporates several novel mechanisms to assure low deuterium content in the mitochondria and other organelles. Nicotinamide adenine dinucleotide (NAD) is a major carrier of deuterium-depleted protons to supply the mitochondria. Many enzymes, especially flavoproteins, are able to use proton tunneling to fractionate out deuterium.

Effects on Cell Cycle Regulation and Oncogene Expression

Studies have shown that DDW induced apoptosis in cancer cells, both in vitro and in vivo. The inhibitory effect of DDW on the expression of proto-oncogenes such as c-Myc, Ha-ras, and p53 has also been documented. Complete or partial tumor regression has been established in mice xenografts with MDA-MB-231, MCF-7 human breast adenocarcinoma cell lines and PC-3 human prostate tumor cells. When laboratory animals were exposed to chemical carcinogenesis by 7,12-dimethyl-benzanthracene (DMBA), cytoplasmic myelocytomatosis oncogenes, c-Myc, Ha-ras, and p53 were up-regulated, while DDW, applied as drinking water, suppressed the expression of these oncogenes.

Effects on Reactive Oxygen Species (ROS) and Oxidative Stress

Theoretically, deuterium disrupts ATP synthesis in mitochondria, causing increased production of reactive oxygen species and reduced synthesis of ATP. Conversely, when deuterium is depleted, this burden on the electron transport chain is reduced. Deuterium-depleted water has been shown to possess various effects including reducing free radical oxidation and counteracting oxidative stress-mediated cellular damage by inducing endogenous antioxidants in cells.

Deuterium in Food and Dietary Sources

Recent studies indicate diet as the main source of increased fatty acid pool in plasma; thus, production of ketones using deuterium-depleted fatty acids might illustrate the benefit of ketogenic diets in a breast cancer epidemiological study. Large variations in fatty and amino acid natural ²H/¹H ratios in reference with solvent water point to the active involvement of compartmental, inter- and intramolecular deuterium disequilibrium in adaptive biology.

4. Scientific Evidence by Area of Use

4.1 Cancer: Preclinical Evidence

Deuterium depletion, achieved through deuterium-depleted water (DDW), has shown anticancer effects in vitro, in vivo, and in Phase 2 prospective and retrospective clinical studies. Over thirty years of basic research has demonstrated that the deuterium-to-hydrogen ratio plays a pivotal role in regulating metabolism and cell growth via a sub-molecular regulatory system that orchestrates the intricate complexity of life in eukaryotic organisms.

It has been demonstrated that replacing regular water (with 16 mmol/L D concentration, equivalent to 150 ppm, as found in natural waters) with deuterium-depleted water (3.2 mmol/L D concentration, equivalent to 30 ppm) inhibits cell growth in vitro and leads to complete tumor regression in vivo. Conversely, research has also shown that deuterium-enriched water, containing deuterium in 2–4-fold concentrations above natural levels (300–600 ppm), stimulates cell growth.

Tumorigenesis involves a metabolic switch that supports increased cellular deuterium levels, decreasing the deuterium burden overall in the organism. Results from systematic reviews showed that DDW alone or in combination with chemotherapy effectively inhibited cancer progression in most experiments. The combination treatment enhances the therapeutic effect on cancer compared with chemotherapeutic monotherapy.

4.2 Cancer: Clinical Evidence

Prostate Cancer (Phase II, Randomized, Double-Blind Trial): In HYD's Phase 2, double-blind, randomized trial, out of 44 patients undergoing conventional cancer therapy for prostate cancer, 22 patients also received DDW over four months, with the remaining 22 patients receiving placebo. The results showed that patients receiving DDW had a significantly greater reduction in prostate size compared to the placebo group — on average, down 160 cm³ versus 54 cm³. Furthermore, the one-year survival rates were 20 out of 22 in the DDW arm of the study but only 13 out of 22 in the placebo group. The anticancer effect of deuterium depletion has already been confirmed in this double-blind, randomized, 4-month-long Phase 2 clinical trial on prostate cancer, and the extended follow-up suggests that DDW delays the progression of the disease.

Lung Cancer (Clinical Study, 129 Patients): Based on observations that deuterium depletion inhibits the growth of cancer cell lines and suppresses certain proto-oncogenes, a clinical study was conducted in 129 patients with small cell and non-small cell lung cancers who consumed deuterium-depleted drinking water (DDW) as a nontoxic agent in addition to conventional chemotherapy and radiotherapy. Median survival time (MST) was 25.9 months in males and 74.1 months in female patients; the difference between genders was statistically significant (p < 0.05). Median survival of subjects with brain metastasis was 27.1 months. Cumulative 5-year survival probabilities were 19%, 52%, and 33% in males, females, and all patients with brain metastasis, respectively.

Large Observational Study (2,649 Patients): In a population-based observational study, 2,649 cancer patients undergoing conventional therapy and consuming DDW were included between October 1992 and October 2024. With various cancer types and stages and conventional therapies received, they are representing a broad spectrum of the Hungarian cancer population.

Breast Cancer: Retrospective clinical studies confirmed the anticancer effect of DDW, as the consumption of DDW led to a several-fold increase in the median survival time (MST) of patients with prostate, breast, lung, and pancreatic cancer, respectively.

Limitations of Cancer Evidence: The translation of findings from concept to practice is far from straightforward. Before DDW can be widely implemented in medical practice, it is imperative to address certain issues, such as the optimal dosage, the safety of long-term application, and the cost concerns associated with DDW. Most oncology trials to date have been conducted primarily by one research group in Hungary. HYD is currently seeking investors and/or pharmaceutical companies to conduct a pivotal Phase II/III human clinical study with tumors including glioblastoma, lung cancer, breast cancer, or prostate cancer. Large-scale, independent, Phase III randomized controlled trials have not yet been completed.

4.3 Diabetes and Metabolic Syndrome

Clinical (Phase II) Evidence: In a Phase II clinical study, deuterium depletion reduced fasting glucose concentration and insulin resistance.

Preliminary Human Study (30 Volunteers): In one study, 30 volunteers with pre- or manifest diabetes were enrolled in a clinical study. The patients received 1.5 L of water with reduced deuterium content (104 ppm instead of 145 ppm) daily for 90 days. The effects on fasting glucose and insulin level, on peripheral glucose disposal, and other metabolic parameters were investigated. Fasting insulin and glucose decreased, and insulin reaction on glucose load improved, in 15 subjects, while in the other 15 the changes were opposite.

Animal/Cell Evidence: Animals were randomly distributed into nine groups to test the effect of D₂O (in a range of 25–150 ppm) on glucose metabolism in diabetic animals with or without insulin treatment. Serum glucose, fructose amine, HbA1c, insulin, and urine glucose levels were monitored. After the 8-week treatment, the optimal concentration of deuterium was found to be between 125 and 140 ppm. These data suggest that deuterium depletion dose-dependently enhances the effect of insulin on GLUT4 translocation and potentiates glucose uptake in diabetic rats. Based on the experimental data, deuterium-depleted water could be used to treat patients with metabolic syndrome by increasing insulin sensitivity.

GLUT4 gene expression significantly increased under deuterium depletion, reaching a maximum value at a deuterium concentration of approximately 50 ppm, which was approximately nine times that of natural water with a deuterium concentration of 150 ppm. GLUT4 protein also showed an increase at similar DDW concentrations.

Evidence strength: Preliminary. The human study was small (n=30) and showed mixed results; animal and cellular data are more consistent. Independent replication in larger trials is lacking.

4.4 Neurological and Psychological Effects: Depression and Memory

Subsequent studies have shown a positive correlation between the D-content in drinking water and human susceptibility to depression, and found the effects of DDW on stimulating long-term memory in rats. Deuterium-depleted water has shown tremendous potential in the adjuvant treatment of diseases such as tumors, depression, diabetes, and metabolic syndrome, opening new avenues for the treatment of these disorders and diseases.

Evidence strength: The evidence for depression is epidemiological (correlational) and preclinical (animal models). No controlled human clinical trials for depression or memory have been identified in the literature. This area remains speculative.

4.5 Aging and Longevity

Achieving moderate levels of deuteration by adding 7.5% and 15% D₂O to the regular diet significantly extended the mean lifespan of Drosophila melanogaster without impairing fecundity. DDW has been shown to reverse the shortening of lifespan induced by manganese (Mn) in Caenorhabditis elegans.

Evidence strength: Exclusively preclinical (invertebrate animal models). No human clinical data on aging or longevity are available.

4.6 Obesity and Lipid Metabolism

DDW has been demonstrated to alleviate diet-induced obesity and related metabolic damage in rat models, and to regulate serum parameters associated with diabetes and metabolic syndrome.

Evidence strength: Animal models only. No human clinical trials on obesity outcomes have been identified.

4.7 Hearing Loss

Supplementation with 10% D₂O in the diet of age-related hearing loss (ARHL) mice can effectively slow the metabolic rate and reduce the production of endogenous oxidative stress in the cochlea, thereby impeding the progression of ARHL.

Evidence strength: Animal model only. No human data are available.

4.8 Cardiovascular Effects

Evidence suggested that D₂O at a concentration of 25% could act as a calcium channel blocker to normalize calcium uptake in vascular smooth muscle, thereby preventing hypertension.

Evidence strength: Early experimental data; note that a 25% D₂O concentration is far above naturally occurring or therapeutically administered concentrations. Clinical relevance has not been established.

4.9 Sports Performance

Deuterium depletion was found to have beneficial health effects in sports performance in the scoping review by Korchinsky et al. (2024), though the review itself noted only a single study was available on this topic. Although there was one study available on sports performance, this area is promising. There is abundant space for further research to establish more about deuterium depletion and its effect on human health.

Evidence strength: Single study; preliminary and insufficient to draw conclusions.

5. Body Systems and Health Areas Associated with Deuterium

Oncology / Cancer Biology: The most extensively studied area; existing studies indicate that deuterium, as a relatively rare isotope, is indispensable for maintaining normal cellular function, while its enrichment and depletion can affect living systems at multiple levels, including but not limited to molecules, organelles, cells, organs, and organisms.
Mitochondrial and Energy Metabolism: The ATPase pumps in the mitochondria utilize proton motive force to drive ATP synthesis, and deuterons damage the pumps, producing a stutter that can cause reactive oxygen release and inefficiencies in ATP synthesis.
Endocrine / Metabolic System: Glucose regulation, insulin sensitivity, and metabolic syndrome are linked to deuterium homeostasis in animal and limited human studies.
Central Nervous System: Correlational evidence linking regional water deuterium content to depression rates; animal data on memory enhancement with DDW.
Antioxidant Defense: DDW has been shown to counteract oxidative stress-mediated cellular damage by inducing endogenous antioxidants in cells.
Auditory System: Preclinical evidence only (mouse models of age-related hearing loss).
Gut Microbiome: Gut microbes likely play a significant role in providing deuterium-related metabolic functions, though this remains an emerging area of investigation.

6. Deuterium in Pharmaceutical Drug Development

A distinct and more established application of deuterium is in pharmaceutical drug design — separate from the dietary supplement context of DDW.

A deuterated drug is a small molecule medicinal product in which one or more of the hydrogen atoms in the drug molecule have been replaced by the heavier stable isotope deuterium. Because of the kinetic isotope effect, deuterium-containing drugs may have significantly lower rates of metabolism, and hence a longer half-life, than their non-deuterated isotopologs.

The FDA granted marketing approval for the first deuterated drug molecule, deutetrabenazine (a racemic mixture), which is useful in treating chorea (an involuntary movement disorder) associated with Huntington's disease and tardive dyskinesia. Deutetrabenazine is an analogue of the old drug tetrabenazine, with the two methoxy groups in the latter being replaced by a pair of trideuteromethoxy groups, thereby altering the rate of metabolism to afford greater tolerability and an improved dosing regimen. Deuterium substitution impedes oxidative metabolism of the methoxy groups, in an excellent demonstration of the primary kinetic isotope effect (KIE).

Although some deuterated drugs, notably donafenib and deutetrabenazine, have demonstrated clinically significant efficacy, their limited use is an effect of ongoing challenges with metabolic switching and species-specific variation. The second important milestone in the deuterium journey to the drug market was the development of deucravacitinib, an allosteric tyrosine kinase 2 (TYK2) inhibitor that received approval for the treatment of psoriasis in September 2022.

The applications of the deuterium isotope effect have increased over time, and it is now applied extensively in mechanistic studies of the metabolism of drugs as well as in other studies focused on pharmacokinetics, efficacy, tolerability, bioavailability, and safety.

7. Dosage Forms and Dosages Reported in Studies

The following dosages are reported strictly as they appear in the cited literature and do not constitute recommendations.

DDW for cancer (in vitro / in vivo): Clinical trials demonstrated that drinking DDW containing 10–20 ppm deuterium caused growth arrest of malignant cells in cancer patients.
DDW for cancer (clinical studies): Clinical data show extended survival of prostate, breast, and lung cancer patients who took DDW that contained between 25 and 125 ppm of deuterium.
DDW for metabolic syndrome (human clinical study): Patients received 1.5 L of water with reduced deuterium content (104 ppm instead of 145 ppm) daily for 90 days.
DDW for diabetes (animal model, optimal range): The optimal concentration of deuterium was found to be between 125 and 140 ppm. After a 4-week period of deuterium depletion, the highest membrane-associated GLUT4 content was detected at 125 ppm.
DDW for GLUT4 expression (cell model): GLUT4 gene expression significantly increased under deuterium depletion, reaching a maximum value at a deuterium concentration of approximately 50 ppm.
D₂O in hearing loss (animal model): Supplementation with 10% D₂O in the diet of age-related hearing loss mice was used.
D₂O for Drosophila lifespan extension (animal model): Adding 7.5% and 15% D₂O to the regular diet significantly extended mean lifespan without impairing fecundity.
General DDW production range: DDW of controlled isotopic concentration D/(D+H) within the range of 20–120 ppm can currently be produced.

8. Safety Considerations

Safety of Deuterium-Depleted Water at Dietary Concentrations

While DDW is generally considered safe and nontoxic, relevant evidence on the long-term effect of DDW consumption is scarce, and a thorough investigation is needed. A wide range of anti-cancer drugs in current use are associated with severe adverse effects, while deuterium-depleted water appears to have virtually no pharmacological side effects and is convenient to administer. In different animal studies, deuterium-depleted water had no significant side effects.

Toxicity of High-Dose Heavy Water (D₂O)

While heavy water is not radioactive, consuming it in large quantities can affect biological systems. The slower reaction rate of deuterium can disrupt metabolic reactions in cells, though the small amounts naturally present in the environment are harmless. Heavy water and semi-heavy water cause disorder in vivo reactions when ingested in a large amount, and a living thing dies in pure heavy water.

Potential Adverse Effects on Stem Cells

In one cell study, deuterium-depleted water was toxic to human stem cells in the long run. This study confirmed that the best way to store stem cells is an environment with typical deuterium levels.

Biphasic / Concentration-Dependent Effects

Despite the adverse impacts and toxic effects of deuterium excess on biological systems, at appropriate concentrations, excess deuterium may produce desirable protective effects. For instance, a slight enrichment of deuterium (350 ppm) in water has been shown to accelerate the growth of human cells by reducing the production of reactive oxygen species (ROS) in mitochondria. The overall literature suggests that deuterium's biological effects are strongly concentration-dependent and bidirectional.

Regulatory Status

Deuterium-depleted water has not been approved by the FDA for medical use. DDW is approved in Hungary as an anticancer drug for animals. No major regulatory agency — including the FDA, EMA, or WHO — has approved DDW as a therapeutic product for human use. No official pharmacopeial monograph (USP, European Pharmacopoeia, WHO) for DDW as a dietary supplement has been established.

Vulnerable Populations

Studies haven't evaluated the safety of deuterium-depleted water in childhood, pregnancy, and lactation.

Unresolved Questions

The appropriate dosage of DDW for treating diseases needs to be established, as the optimal dose may vary depending on the type and course of disease, and individual factors such as age and weight. The human deutenome remains an untapped area of energy metabolism and health in humans. Even with limited data, consistent deuterium depletion can be seen across all conditions reviewed in current scoping reviews, though the evidence base is heterogeneous and the number of high-quality human clinical trials remains small.

References

Health Conditions

Health conditions that Deuterium may help support.

No conditions available.

Body Systems

Body systems that Deuterium may help support.

No body systems available.